Fipravirimat
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | GSK3640254 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C43H67FN2O4S |
| Molar mass | 727.08 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.
Fipravirimat is being developed by ViiV Healthcare and as of 2023 is in Phase II clinical trials.